Internal Medicine, Gastroenterology · Pittsburgh, PA
NPI
1942317482
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
4815 Liberty Ave, Ste. 453
Pittsburgh, PA, 15224
Phone (412) 578-1907
Groups this clinician bills Medicare through
Medicare paid, 2024
$91K
844 services
Medicare patients, 2024
473
Average age 72
Drug cost, 2024
$197K
2,202 prescriptions
Company payments, 2025
$1,414
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ravi Kondaveeti was code 43239 (upper gi endoscopy), 155 times for 147 patients. In total Ravi Kondaveeti billed 844 services in 42 codes, and Medicare paid $91K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-07-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 43239 Upper GI Endoscopy | Facility | 155 | 147 | $87.70 | $14K |
| 99232 Hospital E&M - Subsequent | Facility | 127 | 57 | $58.22 | $7,394 |
| 45385 Colonoscopy - Lesion Removal | Facility | 103 | 103 | $167.68 | $17K |
| 99214 Office E&M - Established | Office | 69 | 57 | $89.12 | $6,149 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 47 | 47 | $162.59 | $7,642 |
| 45380 Lower GI Endoscopy - Other | Facility | 43 | 41 | $92.56 | $3,980 |
| 99222 Hospital E&M - Initial | Facility | 43 | 39 | $99.44 | $4,276 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 34 | 34 | $170.52 | $5,798 |
| 99213 Office E&M - Established | Office | 27 | 24 | $55.65 | $1,503 |
| 45390 Lower GI Endoscopy - Other | Facility | 20 | 20 | $244.78 | $4,896 |
| 45378 Lower GI Endoscopy - Other | Facility | 20 | 19 | $115.38 | $2,308 |
| 99204 Office E&M - New | Office | 16 | 16 | $95.19 | $1,523 |
| 99203 Office E&M - New | Office | 14 | 14 | $78.18 | $1,095 |
| 45330 Lower GI Endoscopy - Other | Facility | 13 | 12 | $41.00 | $533 |
| 45385 Colonoscopy - Lesion Removal | Office | 12 | 12 | $131.64 | $1,580 |
By year: 2022 $124K for 1,380 services; 2023 $117K for 1,168 services; 2024 $91K for 844 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ravi Kondaveeti prescribed most often to Medicare patients was Gavilyte-G (Peg3350/Sod Sulf,bicarb,cl/Kcl), with 711 prescriptions and refills. In total Ravi Kondaveeti wrote 2,202 Medicare prescriptions that cost $197K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 711 | 711 | 662 | $9,910 |
| Pantoprazole Sodium Generic | 438 | 987 | 202 | $6,876 |
| Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl | 304 | 304 | 288 | $4,571 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 242 | 242 | 237 | $16K |
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | 86 | 86 | 85 | $2,170 |
| Famotidine Generic | 70 | 168 | 26 | $745 |
| Omeprazole Generic | 53 | 125 | 25 | $1,095 |
| Mesalamine Er Mesalamine | 38 | 84 | 16 | $27K |
| Sucralfate Generic | 24 | 41 | Under 11 | $1,725 |
| Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl | 22 | 22 | 22 | $365 |
| Cholestyramine Cholestyramine (With Sugar) | 18 | 28 | Under 11 | $1,178 |
| Mesalamine Generic | 17 | 32 | Under 11 | $9,635 |
| Sulfasalazine Generic | 15 | 21 | Under 11 | $580 |
| Lansoprazole Generic | 15 | 27 | Under 11 | $361 |
| Esomeprazole Magnesium Generic | 12 | 32 | Under 11 | $340 |
Brand drugs: 429 claims; generic drugs: 1,773 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ravi Kondaveeti $1,414 ($1,414 in general payments such as food, travel and fees) from 7 companies. The largest payer was Takeda Pharmaceuticals U.S.A., Inc. with $578.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.